5-氟-6-甲氧基吡啶-3-硼酸 | 856250-60-7

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-氟-6-甲氧基吡啶-3-硼酸
• 中文别名: 2-甲氧基-3-氟吡啶-5-硼酸
• 英文名称: (5-fluoro-6-methoxypyridin-3-yl)boronic acid
• 英文别名: (5-fluoro-6-methoxy-3-pyridyl)boronic acid
• CAS: 856250-60-7
• 化学式: C₆H₇BFNO₃
• mdl: MFCD04112520
• 分子量: 170.936
• InChiKey: OCWTXKZPAZAQQW-UHFFFAOYSA-N

物化性质

• 沸点：
  308.3±52.0 °C(Predicted)
• 密度：
  1.34

计算性质

• 辛醇/水分配系数(LogP)：
  0.91
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  62.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Fluoro-2-methoxypyridine-5-boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Fluoro-2-methoxypyridine-5-boronic acid
CAS number: 856250-60-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7BFNO3
Molecular weight: 170.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氟-6-甲氧基吡啶-3-硼酸 在 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 水 、 甲酸铵 、 三乙胺 、 cesium fluoride 、 fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate 、 sodium hydroxide 作用下， 以 甲醇 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 572.0h， 生成
  参考文献：
  名称：

  [EN] HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET MÉTHODES D'UTILISATION ASSOCIÉES

  摘要：

  提供了一些组蛋白去乙酰化酶（HDAC）抑制剂，其化学公式为I，包括它们的组合物及使用方法。

  公开号：

  WO2014159224A1

文献信息

• [EN] 6-PHENYLPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS DE 6-PHÉNYLPYRIDO [2,3-D] PYRIMIDINE EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：ACHAOGEN INC

  公开号：WO2018023081A1

  公开（公告）日：2018-02-01

  The disclosure relates to antibacterial compounds having the Formula (I), where R1, R2, R3, R4, R8, n, and p are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.

  本公开涉及具有公式(I)的抗菌化合物，其中R1、R2、R3、R4、R8、n和p如本文所述，以及所述化合物的立体异构体、药物可接受的盐、酯和前药，包含此类化合物的药物组合物，通过给予此类化合物来治疗细菌感染的方法，以及制备这些化合物的方法。
• Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase
  作者：Logan D. Andrews、Timothy R. Kane、Paola Dozzo、Cat M. Haglund、Darin J. Hilderbrandt、Martin S. Linsell、Timothy Machajewski、Glen McEnroe、Alisa W. Serio、Kenneth B. Wlasichuk、David B. Neau、Svetlana Pakhomova、Grover L. Waldrop、Marc Sharp、Joe Pogliano、Ryan T. Cirz、Frederick Cohen

  DOI：10.1021/acs.jmedchem.9b00625

  日期：2019.8.22

  A major challenge for new antibiotic discovery is predicting the physicochemical properties that enable small molecules to permeate Gram-negative bacterial membranes. We have applied physicochemical lessons from previous work to redesign and improve the antibacterial potency of pyridopyrimidine inhibitors of biotin carboxylase (BC) by up to 64-fold and 16-fold against Escherichia coli and Pseudomonas

  新抗生素发现的主要挑战是预测使小分子渗透到革兰氏阴性细菌膜的理化特性。我们从以前的工作中吸取了物理化学教训，以重新设计和提高生物素羧化酶（BC）的吡啶嘧啶抑制剂对大肠杆菌和铜绿假单胞菌的抗菌效力，分别提高了64倍和16倍。在存在外膜通透剂的情况下或在流出抑制菌株中的抗菌和酶效能评估表明，许多重新设计的BC抑制剂的渗透性和流出特性可以在不同程度上得到改善。对铜绿假单胞菌中改良的嘧啶嘧啶抑制剂的自发抗性在10-8和10-9之间的极低频率下发生。然而，与亲本菌株相比，抗药性菌株的最低抑菌浓度变化惊人地高（16-> 128倍）。抗性分离株的全基因组测序表明，BC靶点突变或外排泵过表达均可导致高水平抗性的发展。
• [EN] IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] MODULATEURS DE 5,6-BICYCLO-IMIDAZO[1,2-A]PYRAZINE DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：SELVITA S A

  公开号：WO2019002606A1

  公开（公告）日：2019-01-03

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues,or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer, isotopologues,or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

  本发明涉及式(I)的化合物及其盐、立体异构体、互变异构体、同位素同分异构体或N-氧化物。本发明进一步涉及将该化合物或盐、立体异构体、互变异构体、同位素同分异构体或N-氧化物用作药物的用途，以及包含该化合物的药物组合物。
• Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment
  作者：Songwen Lin、Chunyang Wang、Ming Ji、Deyu Wu、Yuanhao Lv、Kehui Zhang、Yi Dong、Jing Jin、Jiajing Chen、Jingbo Zhang、Li Sheng、Yan Li、Xiaoguang Chen、Heng Xu

  DOI：10.1021/acs.jmedchem.8b00416

  日期：2018.7.26

  intensive efforts to develop new cancer therapeutics that target this pathway. In this work, we discovered a series of novel 2-amino-4-methylquinazoline derivatives through a hybridization and subsequent scaffold hopping approach that were highly potent class I PI3K inhibitors. Lead optimization resulted in several promising compounds (e.g., 19, 20, 37, and 43) with nanomolar PI3K potencies, prominent

  磷脂酰肌醇3激酶（PI3K）信号的增加是癌症中最常见的变化之一，促使人们投入大量精力开发针对该途径的新型癌症疗法。在这项工作中，我们通过杂交和随后的支架跳跃方法发现了一系列新型的2-氨基-4-甲基喹唑啉衍生物，它们是高效的I类PI3K抑制剂。先导物优化导致了几个有前途的化合物（例如，19，20，37，和43）以纳摩尔效力PI3K，突出的抗增殖活性，有利的PK曲线，以及在体内抗肿瘤效力的鲁棒性。更有趣的是，与19和20相比，37和图43显示了在原位胶质母细胞瘤异种移植模型中改善的脑渗透和体内功效。此外，进行了初步的安全性评估，包括hERG通道抑制，AMES，CYP450抑制和单剂量毒性，以表征其毒理学特性。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：CELLCENTRIC LTD

  公开号：WO2018073586A1

  公开（公告）日：2018-04-26

  A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

  一种化合物，其为式(I)的芳基咪唑基异噁唑（化学式(I)）或其药用可接受的盐。该化合物具有调节p300和/或CBP活性的作用，并用于治疗癌症，特别是前列腺癌。